H.C. Wainwright raised the firm’s price target on United Therapeutics to $400 from $300 and keeps a Buy rating on the shares. The analyst cites the company’s accelerated share repurchase program for the target increase.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Truist biotech analyst holds an analyst/industry conference call
- United Therapeutics price target raised to $350 from $270 at TD Cowen
- United Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
- United Therapeutics announces full enrollment of TETON 2 study
- United Therapeutics price target raised to $370 from $300 at UBS